Immune Responses in Macaques to a Prototype Recombinant Adenovirus Live Oral Human Papillomavirus 16 Vaccine

Clinical and Vaccine Immunology

Volumn 21, Issue 9, 2014, Pages 1224-1231

  Berg, Michael G ^a,d   Adams, Robert J ^b   Gambhira, Ratish ^c   Siracusa, Mark C ^a,e   Scott, Alan L ^a   Roden, Richard B S ^c   Ketner, Gary ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Molecular and Comparative Pathobiology ^*  (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ABBOTT DIAGNOSTICS   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; FEMALE; HOST RANGE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; MACACA NEMESTRINA; NONHUMAN; PRIORITY JOURNAL; VIRION; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS TRANSCRIPTION; VIRUS TYPING; ANIMAL; BLOOD; GENETICS; HUMAN ADENOVIRUS C; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAPILLOMAVIRUS INFECTIONS; T LYMPHOCYTE;

ADENOVIRUSES, HUMAN; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DRUG CARRIERS; FEMALE; HUMAN PAPILLOMAVIRUS 16; MACACA NEMESTRINA; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84919495328     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00197-14     Document Type: Article

References (38)

1. Gaydos CA, Gray GC. 2008. Adenovirus vaccine, p 1103-1122. In Plotkin SA, Orenstein MD, Offit P (ed), Vaccines, Saunders, Philadelphia, PA.
2. Lu B, Kumar A, Castellsagué X, Giuliano AR. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect. Dis. 11:13. http://dx.doi.org/10.1186/1471-2334-11-13.
3. Lowy DR, Schiller JT. 2012. Reducing HPV-associated cancer globally. Cancer Prev. Res. (Phila.) 5:18-23. http://dx.doi.org/10.1158/1940-6207.CAPR-11- 0542.
4. Berg M, Difatta J, Hoiczyk E, Schlegel R, Ketner G. 2005. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc. Natl. Acad. Sci. U. S. A. 102:4590-4595. http://dx.doi.org/10.1073/pnas.0500933102. (Pubitemid 40397156)
5. Berg M, Gambhira R, Siracusa M, Hoiczyk E, Roden R, Ketner G. 2007. HPV16 L1 capsid protein expressed from viable adenovirus recombinants elicits neutralizing antibody in mice. Vaccine 25:3501-3510. http://dx.doi.org/10.1016/ j.vaccine.2006.06.080. (Pubitemid 46527981)
6. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292. http://dx.doi.org/10.1093/jnci/93.4.284. (Pubitemid 32219815)
7. Pinto LA, Viscidi R, Harro CD, Kemp TJ, García-Piñeres AJ, Trivett M, Demuth F, Lowy DR, Schiller JT, Berzofsky JA, Hildesheim A. 2006. Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. Virology 353:451-462. http://dx.doi.org/10.1016/j.virol.2006.06.021. (Pubitemid 44397148)
8. Tobery TW, Smith JF, Kuklin N, Skulsky D, Ackerson C, Huang L, Chen L, Cook JC, McClements WL, Jansen KU. 2003. Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cellmediated immune responses in immunized rhesus macaques. Vaccine 21:1539-1547. http://dx.doi.org/10.1016/ S0264-410X(02)00679-5. (Pubitemid 36263196)
9. Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M. 1997. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71:8531-8541. (Pubitemid 27446435)
10. Klessig DF, Grodzicker T. 1979. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17:957-966. (Pubitemid 9252303)
11. Challberg SS, Ketner G. 1981. Deletion mutants of adenovirus 2: isolation and initial characterization of virus carrying mutations near the right end of the viral genome. Virology 114:196-209. (Pubitemid 11007417)
12. Sharma DP, Anderson M, Zink MC, Adams RJ, Donnenberg AD, Clements JE, Narayan O. 1992. Pathogenesis of acute infection in rhesus macaques with a lymphocyte-tropic strain of simian immunodeficiency virus. J. Infect. Dis. 166:738-746. http://dx.doi.org/10.1093/infdis/166.4.738.
13. Buck CB, Pastrana DV, Lowy DR, Schiller JT. 2004. Efficient intracellular assembly of papillomaviral vectors. J. Virol. 78:751-757. http://dx.doi.org/10. 1128/JVI.78.2.751-757.2004. (Pubitemid 38067597)
14. Pastrana DV, Buck CB, Pang YY, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216. http://dx.doi.org/10.1016/j.virol. 2003.12.027. (Pubitemid 38406035)
15. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-74. http://dx.doi.org/10.1099/0022-1317-36-1-59.
16. Andrade F, Bull HG, Thornberry NA, Ketner GW, Casciola-Rosen LA, Rosen A. 2001. Adenovirus L4-100K assembly protein is a granzyme B substrate that potently inhibits granzyme B-mediated cell death. Immunity. 14:751-761. http://dx.doi.org/10.1016/S1074-7613(01)00149-2. (Pubitemid 32592422)
17. Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT, Wallace D, Kopp W, Adelsberger JW, Baseler MW, Berzofsky JA, Hildesheim A. 2003. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J. Infect. Dis. 188:327-338. http://dx.doi.org/10.1086/376505. (Pubitemid 36898167)
18. Gómez-Román VR, Grimes GJ, Jr, Potti GK, Peng B, Demberg T, Gravlin L, Treece J, Pal R, Lee EM, Alvord WG, Markham PD, Robert-Guroff M. 2006. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine 24:5064-5072. http://dx.doi.org/10.1016/j.vaccine.2006.03.048.
19. Philipson L, Lonberg-Holm K, Pettersson U. 1968. Virus-receptor interaction in an adenovirus system. J. Virol. 2:1064-1075.
20. Frazer IH. 2004. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol. 4:46-54. http://dx.doi.org/10.1038/nri1260. (Pubitemid 38084131)
21. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K, Kalvanaraman VS, Pavlakis GN, Robert-Guroff M. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J. Virol. 77:8607-8620. http://dx.doi.org/10.1128/JVI.77.16.8607-8620.2003. (Pubitemid 36936072)
22. Malkevitch N, Patterson LJ, Aldrich K, Richardson E, Alvord WG, Robert-Guroff M. 2003. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/ subunit protein boosting vaccine regimen induces broad, persistent SIVspecific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J. Immunol. 170:4281-4289. http://dx.doi.org/10.4049/jimmunol.170.8.4281. (Pubitemid 36428196)
23. Gurwith M, Lock M, Taylor EM, Ishioka G, Alexander J, Mayall T, Ervin JE, Greenberg RN, Strout C, Treanor JJ, Webby R, Wright PF. 2013. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect. Dis. 13:238-250. http://dx.doi.org/10.1016/S1473-3099(12)70345-6.
24. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81: 4654-4663. http://dx.doi.org/10.1128/JVI.02696- 06. (Pubitemid 46668663)
25. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, Lin SW, Li Y, Giles-Davis W, Cun A, Zhou D, Xiang Z, Letvin NL, Ertl HC. 2007. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J. Virol. 81:6594-6604. http://dx.doi.org/10.1128/JVI.02497-06. (Pubitemid 46878063)
26. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185. http://dx.doi.org/10.4049/ jimmunol.174.11.7179. (Pubitemid 40705685)
27. Patterson LJ, Malkevitch N, Zhao J, Peng B, Robert-Guroff M. 2002. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev. and SIV Nef. DNA Cell Biol. 21:627-635. http://dx.doi.org/10.1089/ 104454902760330165. (Pubitemid 35155685)
28. Schiller JT, Lowy DR. 2012. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 10: 681-692. http://dx.doi.org/10.1038/nrmicro2872.
29. Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK. 2004. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol. 78:3196-3199. http://dx.doi.org/10.1128/JVI.78.6.3196-3199.2004. (Pubitemid 38314381)
30. Alexander J, Ward S, Mendy J, Manayani DJ, Farness P, Avanzini JB, Guenther B, Garduno F, Jow L, Snarsky V, Ishioka G, Dong X, Vang L, Newman MJ, Mayall T. 2012. Pre-clinical evaluation of a replicationcompetent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS One 7:e31177. http://dx.doi.org/10.1371/journal.pone.0031177.
31. Bassett JD, Swift SL, Bramson JL. Optimizing vaccine-induced CD8(+) T-cell immunity: focus on recombinant adenovirus vectors. Expert Rev. Vaccines 10:1307-1319. http://dx.doi.org/10.1586/erv.11.88.
32. Bellone S, El-Sahwi K, Cocco E, Casagrande F, Cargnelutti M, Palmieri M, Bignotti E, Romani C, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. 2009. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8 cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8 CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol. 83:6779-6789. http://dx.doi.org/10.1128/JVI.02443-08.
33. De Bruijn ML, Greenstone HL, Vermeulen H, Melief CJ, Lowy DR, Schiller JT, Kast WM. 1998. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371-376. (Pubitemid 28489636)
34. Dannenberg AM, Jr. 2010. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin. Microbiol. Rev. 23:781-794. http://dx.doi.org/10.1128/CMR.00005-10.
35. Kirimanjeswara GS, Olmos S, Bakshi CS, Metzger DW. 2008. Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis. Immunol. Rev. 225:244-255. http://dx.doi.org/10.1111/j.1600-065X.2008.00689.x.
36. Tarnvik A. 1989. Nature of protective immunity to Francisella tularensis. Rev. Infect. Dis. 11:440-451. http://dx.doi.org/10.1093/clinids/11.3.440.
37. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Evelina A, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL. 2013. DNA prime/adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8:e55571. http://dx.doi.org/10.1371/journal.pone.0055571.
38. Singh OP, Gidwani K, Kumar R, Nylén S, Jones SL, Boelaert M, Sacks D, Sundar S. 2012. Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin. Vaccine Immunol. 19:961-966. http://dx.doi.org/10.1128/CVI.00143-12.